# Effect of Cabergoline on Weight and Glucose Tolerance

> **NCT01395602** · PHASE1,PHASE2 · COMPLETED · sponsor: **Columbia University** · enrollment: 40 (actual)

## Conditions studied

- Body Weight
- Impaired Glucose Tolerance in Obese

## Interventions

- **DRUG:** Cabergoline
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT01395602
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04
- **Primary completion:** 2003-09
- **Final completion:** 2011-07
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2015-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01395602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01395602, "Effect of Cabergoline on Weight and Glucose Tolerance". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01395602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*